Clinical Trial

A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab

Study acronym: CPAB
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 2, 2024 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Hepatocellular carcinoma (HCC) is the most common liver cancer and a leading cancer death worldwide. Currently, atezolizumab and bevacizumab combination is the standard of care for patients with advanced HCC. There have not been proven therapy for patients with advanced HCC previously treated with atezolizumab and bevacizumab. Cabozantinib is a proven therapy for patients with advanced HCC previously treated with sorafenib. The study aims to demonstrate the efficacy and safety of cabozantinib in patients with advanced previously treated with atezolziumab and bevacizumab. It is a multi-center single-arm study which all participants will receive cabozantinib. Participants will continue cabozantinib until. disease progression or unacceptable toxicities.
Trial Details
NCT Number NCT06535737
Lead Sponsor Chulalongkorn University
Collaborators: Mahidol University
Conditions Hepatocellular Carcinoma Non-resectable
Enrollment 40 participants
Start Date 2024-08
Primary Completion 2026-07 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-02